Senate committee OKs generics bill

Share this article:
The Senate Judiciary Committee has approved the Preserve Access to Affordable Generics Act, sponsored by Herb Kohl (D-WI), that would prohibit innovator drug companies from compensating generic drug companies to delay a generic drug’s entry into the market.

The bill would make it illegal for any person, in connection with the sale of a drug product, to directly or indirectly be party to any agreement resolving or settling a patent infringement claim in which an Abbreviated New Drug Application (ANDA) filer receives anything of value. And the ANDA filer would agree not to research, develop, manufacture, market or sell the ANDA product for any period of time.

The legislation also would require the Federal Trade Commission to study:
• The prevalence of agreements in patent infringement suits;
• The impact of such agreements on drug industry competition;
• The prevalence in the drug industry of other anticompetitive agreements among competitors or other practices contrary to the antitrust laws;
• And the impact of such agreements or practices on competition in the drug market in the last five years.

Share this article:
close

Next Article in News

Email Newsletters

More in News

Eli Lilly and BI's Jardiance hits shelves

Eli Lilly and BI's Jardiance hits shelves

The new SGLT-2 inhibitor is on shelves less than a month after FDA approval.

PhRMA Urges Court to Reject Off-Label Promotion Case

PhRMA Urges Court to Reject Off-Label Promotion Case

The Pharmaceutical Research and Manufacturers of America (PhRMA) says a California federal court should dismiss a whistleblower's False Claims Act suit against three drug companies on First Amendment grounds

Five things for Pharma Marketers to know: Tuesday, August 26

Five things for Pharma Marketers to know: Tuesday, ...

Merck and Pfizer pursue new pembrolizumab research, black box warnings are linked to fewer court visits, and the WHO says it needs $430M to fight Ebola.